News

Virginia Tech Corporate Research Center selected to lead innovative new lab space model in SWVA

The Virginia Tech Corporate Research Center (VTCRC) in partnership with the Virginia Tech Foundation (VTF) has been awarded a grant from the GO Virginia program to fund the evaluation and design of new lab concepts to serve southwest Virginia’s growing life and health sciences industry. The award is part of the Enhanced Capacity Building program that will support Virginia’s Region 2.

“We’re honored to be selected to lead this project. The VTCRC is dedicated to making flexible lab space more accessible for smaller startups as well as some of our high-growth companies. This effort will lead to much-needed resources that will help us grow our biotech industry, recruit new companies, and create valuable jobs for our local economy,” said Brett Malone, Ph.D., CEO of the VTCRC.

VTCRC is committed to creating opportunity for growth in Region 2 by leading the design and development of creative lab facilities. The goal is to build on Virginia Tech’s growing presence in the Roanoke Innovation Corridor and in Montgomery County at the VTCRC. This project will be spearheaded by the VTCRC and will include input and guidance from all relevant stakeholders in the region, including Montgomery County, City of Roanoke, Valleys Innovation Council (VIC), RAMP, Roanoke Blacksburg Technology Council (RBTC), Fralin Biomedical Research Institute at VTC, Onward NRV, New River Valley Regional Commission, Roanoke Regional Partnership, and Link License Launch from Virginia Tech.

VTCRC will lead development of a comprehensive assessment, conceptual design, and associated operational plan to support both Roanoke and Blacksburg’s life and health sciences ecosystem with flexible laboratory space. The scope of the project is to assess the demand and projected growth in need for lab space in Region 2, create a working plan to serve the entire region, and create an initial conceptual design with associated presentation materials to drive investor and market interest. The VTCRC plans to address the needs of functional lab space, recruiting new companies, and retaining talent in the area.

“The impact of the project will be far-ranging and could ultimately lead to 800-1,000 new jobs, helping to retain talent in the region. The life sciences sector in Region 2 is vibrant and expanding, and this project will work to provide a necessity for both existing and emerging biotech companies,” said Raymond Smoot, Chair of the GO Virginia Region 2 Council.

“We are very excited to see this project be launched,” said Michael Friedlander, Virginia Tech’s Vice President for Health Sciences and Technology and director of the Fralin Biomedical Research Institute at VTC. “The development of a facility to allow our entrepreneurial biomedical researchers access to launch their startup companies has always been a key part of the biomedical discovery and implementation vision for Roanoke. Moreover, as the translational research enterprise has grown over the last decade, we increasingly encounter outside companies who express interest a presence on the health sciences campus to have the opportunity to interact with the scientists at the research institute. The GO Virginia grant will allow for a systematic and comprehensive analysis of the needs and opportunities for advancing the health sciences translational ecosystem here in Roanoke – it’s an important next step.”

Once the feasibility project is complete, The VTCRC will review and plan for next steps.

Recent News

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.

04/02/2026

ATCC Receives New CDC Award to Help Fast-track Diagnostic Tests for Future Disease Outbreaks

TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated,